Source: Medicines and Medical Devices Safety Authority (NZ) Revision Year: 2020 Publisher: Pfizer New Zealand Ltd, PO Box 3998, Auckland, New Zealand, 1140
DEPO-MEDROL 40 mg/mL Suspension for Injection.
| Pharmaceutical Form |
|---|
|
Depo-Medrol is a white, aqueous,sterile suspension. |
Each 1 mL vial contians 40 mg/mL methylprednisolone acetate.
Excipients with known effects:
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Methylprednisolone |
Methylprednisolone is a synthetic glucocorticoid and a methyl derivative of prednisolone. Methylprednisolone is a potent anti-inflammatory agent with the capacity to profoundly inhibit the immune system. |
| List of Excipients |
|---|
|
Hydrochloric acid |
40 mg/mL – 1 × 1 mL vial; 5 × 1 mL
Pfizer New Zealand Ltd, PO Box 3998, Auckland, New Zealand, 1140
16 June 1976
| Drug | Countries | |
|---|---|---|
| DEPO-MEDROL | Australia, Brazil, Canada, Ecuador, Estonia, Finland, France, Hong Kong, Croatia, Israel, Japan, Mexico, Netherlands, New Zealand, Poland, Tunisia, Turkey, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
